

Gibson Dunn Advises XOMA Royalty on Acquisition of Mural Oncology

Firm News | August 21, 2025

Gibson Dunn is advising XOMA Royalty Corporation on its acquisition of Mural Oncology plc.

XOMA Royalty is a publicly traded biotech royalty aggregator. Mural Oncology is a biopharmaceutical company focused on discovering and developing immunotherapies for patients with cancer.

Our corporate team is led by partners Ryan Murr and Branden Berns and includes associates Evan Shepherd, Maggie Zhang, and Cody Wong. Partner Pamela Lawrence Endreny and associate Elizabeth Johnson are advising on tax. Partner Cassandra Gaedt-Scheckter and associate Michael Roberts are advising on privacy.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Evan Shepherd](#)

[Cody Wong](#)

[Pamela Lawrence Endreny](#)

[Elizabeth Johnson](#)

[Cassandra L. Gaedt-Scheckter](#)

Related Capabilities

[Life Sciences](#)

[Mergers and Acquisitions](#)